Scholarlink

<p>In recent years, the incidence of penicillin-susceptible <i>S. aureus</i> (PSSA) bloodstream infection (BSI) has increased worldwide. However, the preferred antibiotic remains uncertain due to concerns of inducible resistance to benzylpenicillin. We compared outcomes associated with benzylpenicillin versus other antibiotics and investigated risk factors influencing treatment failure. Patients were grouped into benzylpenicillin and non-benzylpenicillin beta-lactam treatment groups (including anti-staphylococcal penicillins and cephalosporins). The primary outcome was overall treatment failure (30-day all-cause mortality and/or 90-day relapse). Of 335 patients, 74 (22.09%) received benzylpenicillin and 261 (77.91%) received a non-benzylpenicillin beta-lactam. While rates of overall treatment failure (13.51% vs. 17.24%; <i>P</i> = 0.45) and occurrence of adverse drug events (6.76% vs. 7.66%; <i>P</i> = 0.79) were comparable to non-benzylpenicillin beta-lactams, benzylpenicillin showed faster microbiological clearance [3.00&#xa0;days (IQR, 2.00–4.00&#xa0;days) vs. 4.00&#xa0;days (IQR, 3.00–5.00&#xa0;days);<i> P</i> = 0.03] and fewer persistent infections (22.97% vs. 36.02%; <i>P</i> = 0.04), suggesting potential to improve patient outcomes. We also found that unknown source (aOR 4.63, 95% CI 1.47–14.64; <i>P</i> &lt; 0.01) was associated with treatment failure, while review by Infectious Disease (ID) specialists (aOR 0.30, 95% CI 0.12–0.73; <i>P</i> = 0.01) was protective, stressing the importance of early ID referral and thorough source identification. This study highlights benzylpenicillin as an effective treatment for PSSA BSI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antibiotic therapy and clinical outcomes of penicillin-susceptible Staphylococcus aureus (PSSA) bloodstream infection (BSI): a ten-year retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月9日

查看全文
  • Zheng Hong Chua,
  • Sock Hoon Tan,
  • Hoi Tong Mok,
  • Christine B. Teng,
  • Shawn Vasoo,
  • Barnaby E. Young

摘要

In recent years, the incidence of penicillin-susceptible S. aureus (PSSA) bloodstream infection (BSI) has increased worldwide. However, the preferred antibiotic remains uncertain due to concerns of inducible resistance to benzylpenicillin. We compared outcomes associated with benzylpenicillin versus other antibiotics and investigated risk factors influencing treatment failure. Patients were grouped into benzylpenicillin and non-benzylpenicillin beta-lactam treatment groups (including anti-staphylococcal penicillins and cephalosporins). The primary outcome was overall treatment failure (30-day all-cause mortality and/or 90-day relapse). Of 335 patients, 74 (22.09%) received benzylpenicillin and 261 (77.91%) received a non-benzylpenicillin beta-lactam. While rates of overall treatment failure (13.51% vs. 17.24%; P = 0.45) and occurrence of adverse drug events (6.76% vs. 7.66%; P = 0.79) were comparable to non-benzylpenicillin beta-lactams, benzylpenicillin showed faster microbiological clearance [3.00 days (IQR, 2.00–4.00 days) vs. 4.00 days (IQR, 3.00–5.00 days); P = 0.03] and fewer persistent infections (22.97% vs. 36.02%; P = 0.04), suggesting potential to improve patient outcomes. We also found that unknown source (aOR 4.63, 95% CI 1.47–14.64; P < 0.01) was associated with treatment failure, while review by Infectious Disease (ID) specialists (aOR 0.30, 95% CI 0.12–0.73; P = 0.01) was protective, stressing the importance of early ID referral and thorough source identification. This study highlights benzylpenicillin as an effective treatment for PSSA BSI.